Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma

NCT07684287 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07684287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
November 30, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelioid hemangioendothelioma